These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 33292080)
1. Cyclic peptide engineered from phytocystatin inhibitory hairpin loop as an effective modulator of falcipains and potent antimalarial. Mishra M; Singh V; Tellis MB; Joshi RS; Pandey KC; Singh S J Biomol Struct Dyn; 2022 May; 40(8):3642-3654. PubMed ID: 33292080 [TBL] [Abstract][Full Text] [Related]
2. Targeting Cysteine Proteases from Plasmodium falciparum: A General Overview, Rational Drug Design and Computational Approaches for Drug Discovery. Bekono BD; Ntie-Kang F; Owono Owono LC; Megnassan E Curr Drug Targets; 2018; 19(5):501-526. PubMed ID: 28003005 [TBL] [Abstract][Full Text] [Related]
12. Hemoglobin Degrading Proteases of Plasmodium falciparum as Antimalarial Drug Targets. Qidwai T Curr Drug Targets; 2015; 16(10):1133-41. PubMed ID: 25738296 [TBL] [Abstract][Full Text] [Related]
13. Hemoglobin cleavage site-specificity of the Plasmodium falciparum cysteine proteases falcipain-2 and falcipain-3. Subramanian S; Hardt M; Choe Y; Niles RK; Johansen EB; Legac J; Gut J; Kerr ID; Craik CS; Rosenthal PJ PLoS One; 2009; 4(4):e5156. PubMed ID: 19357776 [TBL] [Abstract][Full Text] [Related]
14. Identification of (4-(9H-fluoren-9-yl) piperazin-1-yl) methanone derivatives as falcipain 2 inhibitors active against Plasmodium falciparum cultures. Hernández-González JE; Salas-Sarduy E; Hernández Ramírez LF; Pascual MJ; Álvarez DE; Pabón A; Leite VBP; Pascutti PG; Valiente PA Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2911-2923. PubMed ID: 30253205 [TBL] [Abstract][Full Text] [Related]
15. The impact of whole genome sequence data on drug discovery--a malaria case study. Joachimiak MP; Chang C; Rosenthal PJ; Cohen FE Mol Med; 2001 Oct; 7(10):698-710. PubMed ID: 11713369 [TBL] [Abstract][Full Text] [Related]
16. Comparing sequence and structure of falcipains and human homologs at prodomain and catalytic active site for malarial peptide based inhibitor design. Musyoka TM; Njuguna JN; Tastan Bishop Ö Malar J; 2019 May; 18(1):159. PubMed ID: 31053072 [TBL] [Abstract][Full Text] [Related]
17. Falcipains: Biochemistry, target validation and structure-activity relationship studies of inhibitors as antimalarials. Patra J; Rana D; Arora S; Pal M; Mahindroo N Eur J Med Chem; 2023 Apr; 252():115299. PubMed ID: 36996716 [TBL] [Abstract][Full Text] [Related]
18. Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors. Moura PA; Dame JB; Fidock DA Antimicrob Agents Chemother; 2009 Dec; 53(12):4968-78. PubMed ID: 19752273 [TBL] [Abstract][Full Text] [Related]
19. Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely. Chen W; Huang Z; Wang W; Mao F; Guan L; Tang Y; Jiang H; Li J; Huang J; Jiang L; Zhu J Bioorg Med Chem; 2017 Dec; 25(24):6467-6478. PubMed ID: 29111368 [TBL] [Abstract][Full Text] [Related]
20. Three Decades of Targeting Falcipains to Develop Antiplasmodial Agents: What have we Learned and What can be Done Next? González JEH; Salas-Sarduy E; Alvarez LH; Valiente PA; Arni RK; Pascutti PG Curr Med Chem; 2024; 31(16):2234-2263. PubMed ID: 37711130 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]